Daily Archives: April 6, 2022
Observational study suggests a fourth dose of the Pfizer vaccine provided additional protection against severe disease in patients 60 years of age or older during the Omicron wave in Israel.
6 Apr, 2022 | 10:59h | UTCProtection by a Fourth Dose of BNT162b2 against Omicron in Israel – New England Journal of Medicine
Commentary: Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron— Real-world data show less infection and severity, but long-term benefit less clear – MedPage Today (free registration required)
Related:
Perspective: The evidence on 4th doses of covid vaccines & the thorny question of age thresholds.
U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.
[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.
Covid-19: Fourth vaccine doses—who needs them and why?
[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.
Commentary on Twitter
Just published @NEJM
4th dose vaccine protection in >620,000 people vs 3-doses in >620,000, all age 60+, Omicron wave, Israel
—4-fold lower rate of severe disease, no waning at 6 weeks
—2-fold lower rate of infection, rapidly wanedhttps://t.co/g8uGMXGHD6 pic.twitter.com/D7WHywTI1j— Eric Topol (@EricTopol) April 5, 2022
Retrospective cohort study: Waning COVID-19 vaccine effectiveness for Pfizer and CoronaVac in Malaysia.
6 Apr, 2022 | 10:57h | UTC
Commentary on Twitter
@ICR_NIH RECoVam's
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia in IJID.https://t.co/QwNSRQBKOq• Against infections, both wane after 3-5 months
• Against ICU admission, CoronaVac wane
• Against death, both retain considerable effectiveness— Dr Kalai Peariasamy (@drkalai61) March 22, 2022
Cohort Study: Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US.
6 Apr, 2022 | 10:52h | UTC
Commentary on Twitter
In this cohort study, the incidence rate of #SARSCoV2 infection with Omicron variant was 6 to 8 times that of Delta variant in children younger than 5 years, but severe clinical outcomes were less frequent than with Delta variant. https://t.co/UKiMEznXtX
— JAMA Pediatrics (@JAMAPediatrics) April 1, 2022
M-A: Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives.
6 Apr, 2022 | 10:55h | UTC
RCT: Effects of clazosentan on cerebral vasospasm–related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage.
6 Apr, 2022 | 10:47h | UTC
RCT: Cabotegravir (intramuscular injections every 8 weeks) for the prevention of HIV-1 in women.
6 Apr, 2022 | 10:51h | UTCCabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link to abstract – $ for full-text)
Related:
FDA approves first injectable treatment for HIV pre-exposure prevention.
RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.
Review and M-A: pulmonary rehabilitation for Post-Covid.
6 Apr, 2022 | 10:42h | UTC
Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019.
6 Apr, 2022 | 10:49h | UTCNews Release: Global disparities persist in opioid painkiller access – University College London
Invited Commentary: Closing the global pain divide: balancing access and excess – The Lancet Public Health
Commentary on Twitter (article and images under a Creative Commons Attribution (CC BY 4.0 license)
Just Out @TheLancetPH ?
Global #opioids consumption increased from 2015 to 2019‼️#Disparities in opioid?consumption remained, indicating potential inadequate access to essential pain relief in countries with low consumption?https://t.co/bkcdgLy3ZP pic.twitter.com/RUGl1gbiTw— Gil Morgan (@weoncologists) April 1, 2022
RCT: Oral Roxadustat vs. Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis.
6 Apr, 2022 | 10:45h | UTCRelated:
Randomized Trials: Evaluation of New Treatment for Anemia of Chronic Kidney
Cohort study and updated meta-analysis: greater dietary cholesterol and egg consumption linked to increased risk of overall and CVD mortality.
6 Apr, 2022 | 10:41h | UTC
Guideline: Revision of pharmacological treatment recommendations for cancer pain.
6 Apr, 2022 | 09:49h | UTC
Canadian recommendations on prostate cancer screening and early diagnosis.
6 Apr, 2022 | 09:47h | UTCSee also: Summary of changes
Review: Antiseizure medications for adults with epilepsy.
6 Apr, 2022 | 10:25h | UTCAntiseizure Medications for Adults With Epilepsy: A Review – JAMA (free for a limited period)
Audio Clinical Review: Epilepsy Diagnosis and Treatment in Adults – JAMA
Cohort Study: Recipient and donor outcomes after living-donor liver transplant for unresectable colorectal liver metastases.
6 Apr, 2022 | 10:23h | UTCCommentaries:
Living-Donor Liver Transplant Promising for CRC With Liver Mets – HealthDay
Commentary on Twitter
Study suggests living-donor liver transplant is a promising option for meticulously selected patients with unresectable colorectal cancer liver metastases. https://t.co/p6Jbzb73DL
— JAMA Surgery (@JAMASurgery) March 30, 2022
Review: Metabolic flexibility and its impact on health outcomes.
6 Apr, 2022 | 10:08h | UTCMetabolic Flexibility and Its Impact on Health Outcomes – Mayo Clinic Proceedings
Craniocervical artery dissections: a concise review for clinicians.
6 Apr, 2022 | 10:06h | UTCCraniocervical Artery Dissections: A Concise Review for Clinicians – Mayo Clinic Proceedings
RCT: Erythropoietin not beneficial for patients with acute kidney injury.
6 Apr, 2022 | 10:02h | UTCErythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial – BMC Nephrology
Review: Translational advances in pancreatic ductal adenocarcinoma therapy.
6 Apr, 2022 | 10:05h | UTCTranslational advances in pancreatic ductal adenocarcinoma therapy – Nature Cancer (if the link is paywalled, try this one)
Commentary on Twitter
?Don't miss this beautiful review @NatureCancer on translational advances in pancreatic ductal adenocarcinoma by #AbdelNasserHosein, #StephanieKDougan, #AndrewJAguirre & @Aiims1742
Read it here??https://t.co/t6CWD0KCoxhttps://t.co/6RjCQ5NqNo
— Nature Cancer (@NatureCancer) March 29, 2022
M-A: Advanced computed tomographic localization techniques for primary hyperparathyroidism.
6 Apr, 2022 | 09:57h | UTCAdvanced Computed Tomographic Localization Techniques for Primary Hyperparathyroidism: A Systematic Review and Meta-analysis – JAMA Otolaryngology-Head & Neck Surgery (link to abstract – $ for full-text)
Opinion: Moving xenotransplantation research into human trials will require adjusting our expectations, researchers say.
6 Apr, 2022 | 09:59h | UTCRelated:
After a flurry of firsts, xenotransplantation is suddenly back in the spotlight.
In 1st, US surgeons transplant pig heart into human patient.
Review: Fulminant myocarditis in adults.
6 Apr, 2022 | 09:55h | UTCFulminant myocarditis in adults: a narrative review – Journal of Geriatric Cardiology
RCT: Higher vs. Standard Adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis.
6 Apr, 2022 | 09:56h | UTC
Review: Atrial fibrillation in older adults with cancer.
6 Apr, 2022 | 09:53h | UTCAtrial fibrillation in older adults with cancer – Journal of Geriatric Cardiology
Cohort Study: The five major autoimmune diseases are associated with increased risk of cancer.
6 Apr, 2022 | 09:52h | UTCCommentary: Increased Cancer Risk with Autoimmune Disorders – RheumNow
RCT: Rucaparib vs. standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation.
6 Apr, 2022 | 09:45h | UTCRucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In ARIEL4 phase III trial, pts with BRCA1/2-mut ovarian cancer who received ≥2 chemo regimens received rucaparib or chemo. In the ITT, mPFS was 7.4 mo vs 5.7 mo (HR 0.67, 95% CI 0.52–0.86; P = 0.0017). Three treatment-related deaths occurred w rucaparib https://t.co/G7j7djp6kV
— NatureRevClinOncol (@NatRevClinOncol) March 22, 2022